Bioavailability Enhancement
Our state-of-the-art proprietary eutectic formulation technology is a proven approach for significantly enhancing the bioavailability of even the most difficult to formulate APIs.
Leiden, May 15th, 2023:
SeraNovo and AstraZeneca to collaborate on research projects
SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi compound deal with AstraZeneca (Cambridge, United Kingdom)
The benefits of our technology
Rapid Formulation Development
The quality of our formulations is matched by our development speed. We combine API modelling with high throughput development processes to build the optimum formulation(s) in the shortest time.
Single Step Manufacturing
The only manufacturing operations at SeraNovo are gentle heating and stirring. This simple procedure allows for easy transfer and rapid upscaling of the clinical formulation.
Using Safe Excipients
Our formulations only consist of safe excipients. The right combination of safe excipients is essential, be it for enabling higher exposure during toxicology studies or for moving a product into the clinic.